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Committee: Erin R. Weeda, PharmD 
                        Dunc Williams, PhD 
 
  
 Until recently, there were very little data on the effects of antiepileptic drug (AED) 
exposure in utero. However, in the past two decades, data from several prospective pregnancy 
registries have significantly increased the understanding of the critical risks for major congenital 
malformations associated with several AEDs (Gerard & Meador, 2015). This research examined 
the risks associated with valproate among women of childbearing age (18-44 years of age) and 
the risks valproate poses for a child through maternal exposure. The study population came from 
the 2016-2018 MarketScan® Commercial dataset obtained by the Medical University of South 
Carolina. In total, there were n=877 women aged 18-44 years of age. There were n=318 women 
with greater than 3 months prescribed valproate, and there were n=149 women based on 6 month 
pre-index insurance and 12 months post-index insurance where the data index was the date from 
which the first valproate prescription was filled. This led to a final cohort size of 149 women. 
The data was analyzed using measures of central tendency. Tests for differences between those 
on birth control and those not on birth control were made using Student’s t-test for normally 
distributed data, Wilcoxon-Mann-Whitney for non-normally distributed data, and chi-squared 
tests for categorical data. Results include 14.5% of the original population being prescribed 
valproate for 3 or more months, 33.6% being for migraines, followed by 31.5% for bipolar 
disorder despite research being conducted primarily for those with epilepsy. 
 In conclusion, the research shows the need for further education on the risks of valproate 
and women of childbearing age. This is based on the lack of studies focusing on the risks and 
prescribing patterns outside of the epilepsy community. The research limitations included the 
length and type of contraceptive use, which the study could not account for as only measurable 
pregnancy prevention methods were studied. Future research could explore different funding 
streams as our research focused on commercial payor billing data, which garnered a small 
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 Valproate, classified as an anticonvulsant or antiepileptic drug (AED), has several 
modalities. The pharmaceutical is available as an extended-release formulation in capsule form, 
as a delayed-release formulation in tablet form, a sprinkle capsule, or syrup (AHFS, 2020). 
Valproate was first introduced for human use in 1967 in Europe, and its use was licensed in the 
United Kingdom in 1975. It was not until 1978 that it became clinically available in the United 
States as an immediate-release formulation and then again in 1983 as alternative formulations 
(Adab et al., 2004). 
 The U.S. Food and Drug Administration (FDA) initially approved valproate to treat 
seizures, but some valproate products are also approved to treat other ailments. Valproate is 
widely popular for its broad range of anticonvulsant effects and that it also has limited sedative 
and behavioral outcomes compared to other AEDs (Alsdorf & Wyszynski, 2005). Additionally, 
it is recognized as one of the most critical AEDs for its wide spectrum effectiveness and is most 
notable in the acute treatment of bipolar disorder (Alsdorf & Wyszynski, 2005). Valproate 
products include valproate sodium, divalproex sodium, valproic acid, and other generics (FDA, 
2015). As a result, the term valproate was be used to encompass the numerous varieties of the 
drug.  
 Valproate entered the market as a therapeutic intervention for absence seizures. Since 
then, its use has expanded to include the treatment of complex and partial seizures, as well as a 
preventative for migraines in some countries, a treatment for acute mania, and as a mood 
stabilizer for bipolar disorder (Macfarlane & Greenhalgh, 2018; Wyszynski et al., 2005). 





include 67% for psychiatric and mood disorders, 9% for migraines, and 9% for epilepsy in the 
United States (Angus-Leppan & Liu, 2018).  
 Furthermore, valproate is said to cross the placenta and present a higher concentration in 
the child than in the mother (Alsdorf & Wyszynski, 2005). Additionally, valproate is known to 
induce apoptosis, a programmed cell death typically occurring in early development to eliminate 
unwanted cells (NIH, n.d.; Velez-Ruiz & Meador, 2015). Furthermore, valproate is associated 
with a significant risk increase for teratogenesis, production of malformations in a child, 
compared to the baseline population rates and other ordinary AEDs for over 30 years of clinical 
studies (Gerard & Meador, 2015; Jentink et al., 2010).  
 In a 1983 Morbidity and Mortality Weekly Report from the CDC, valproate was stated to 
be a new cause of congenital malformations (CDC, 1983). The report found a significant 
association between valproate exposure during the first trimester of pregnancy and spina bifida 
and concluded that valproate should be considered a human teratogen (CDC, 1983). Since then, 
many factors are said to contribute to the teratogenic properties. Some of these factors include 
drug dosage, gestational age of the child at the time of the exposure, and differences in 
metabolism between the mother and child (Alsdorf & Wyszynski, 2005).   
 Valproate's teratogenic properties have since been evidenced by clinical studies such as 
those done by Weston et al. (2016), Christensen et al. (2013), and Eriksson et al. (2005). In 
addition, national and international pregnancy registries have increasingly identified AEDs' 
teratogenic properties (Alsdorf & Wyszynski, 2005; Tomson et al., 2011). Furthermore, across 
several of these human studies, valproate has been the most highly associated with cognitive and 
behavioral teratogenesis of all AEDs (Gerard & Meador, 2015). In the end, clinical research has 





developmental delays, reduced cognitive function, and, most recently, autism (Roullet et al., 
2013). 
 Notably, animal studies have shown that the timing of exposure affects the type of 
identified malformations. For example, valproate exposure during the first trimester of gestation 
results in malformations of major organs. By contrast, exposure later in pregnancy results in an 
increased risk of neurodevelopmental defects when brain cells proliferate and migrate (Alsdorf & 
Wyszynski, 2005). Animal studies examining valproate have recently shown autistic-like 
outcomes, including social behavior deficits, increased repetitive behaviors, and communication 
deficits (Roullet et al., 2013). 
 Today, an increasing number of pregnant women continue to be exposed to valproate, 
despite its use during the first trimester being associated with an increased risk of spina bifida 
(Jentink et al., 2010; Koren, 2006). Adab et al. (2001) say that roughly one-third of all people 
receiving AEDs were women of childbearing age in 2001. In addition, 1 in 250 pregnancies was 
exposed to AEDs whereby over one million women with epilepsy in the United States were of 
childbearing age, and three to five births per 1,000 were to those women in 2015 (Adab et al., 
2001). Additionally, it was estimated that 1.5 million individuals were prescribed valproate, in 
2012 and roughly 22% of those were women of childbearing age (Angus-Leppan. & Liu, 2018). 
The total number of children exposed to AEDs, including valproate, however, is likely to be 
more noteworthy due to their use as treatments for other conditions (Velez-Ruiz & Meador, 
2015).  
 Not long after valproate was introduced for clinical use in epilepsy, emerging cases 
suggested those increased risk of neural tube defects, including spina bifida (Koren et al., 2006; 





be as much as a two- to three-fold risk increase in congenital malformations among babies born 
to women with epilepsy on valproate compared to the general population (Adab et al., 2001).   
 Jentink et al. (2010) found in their review of published cohort studies that there were 14 
significant malformations more commonly associated with valproate through various 
antiepileptic databases. There was a major congenital malformation observed in 118 of 1,565 
pregnancies. For these malformations, the risk appeared to be significantly higher with the 
association of exposure to valproate during the first trimester of pregnancy compared to those 
with no exposure to antiepileptic drugs during the first trimester (Jentink et al., 2010).  
 The researchers found significant associations between exposure to valproate 
monotherapy in the first trimester in six conditions: spina bifida, cleft palate, atrial septal defect, 
hypospadias, polydactyly, and craniosynostosis. In addition, the researchers found that the risks 
for five of the conditions were two to seven times higher for exposed children. Specifically, the 
risk for spina bifida was as much as 16 times higher for exposed children depending on the 
control group used. Researchers also found an association between limb defects and exposure to 
valproate compared to other drugs used as an antiepileptic (Jentink et al., 2010).  
 In 1984, Fetal Valproate Syndrome first started being used to describe the prominent 
malformations observed in children exposed to valproate in utero. This term refers to a collection 
of minor and major malformations occurring in exposed children, often consisting of facial 
malformations, including a flat nasal bridge, small upturned nose, and thin upper lip, as well as 
multiple major malformations and central nervous system dysfunctions (Wyszynski et al., 2005). 
 Additionally, valproate also causes severe malformations that primarily affect the brain 





intellectual ability is seen in 30% to 40% of children born to mothers who took valproate (AHFS, 
2020; Sawhney et al., 2019). This exposure to valproate affects a child's development during 
pregnancy with a significant IQ reduction compared to children exposed to other AEDs. The IQ 
reductions (8-11 points lower) are considered substantial enough to affect their education and 
affect them later in life when entering the workforce (Tomson et al., 2015). Children exposed to 
valproate in utero have a delay in achieving developmental milestones, particularly verbal skills. 
This delay includes communication problems, including talking, poor language skills. 
Additionally, valproate also can cause coordination problems, including walking and learning 
problems affecting memory, emotions, and behavior (AHFS, 2020; Gerard & Meador, 2015; 
Sawhney et al., 2019). 
 Recently it has been found that children exposed to valproate are more likely to 
demonstrate poor adaptive skills and a heightened risk for neurodevelopmental disorders, 
including attention deficit hyperactivity disorder and autism (Gerard & Meador, 2015). Evidence 
supports this link between cognitive function and the increased risk of autism with valproate 
exposure (Roullet et al., 2013). 
 Of all the AEDs available, the use of valproate during childbearing years and pregnancy 
has raised the most notable concerns (Roullet et al., 2013). FDA warnings related to valproate 
during pregnancy have emphasized the need for reassessment in its use clinically during these 
years (Roullet et al., 2013). Hence, despite its known risks, valproate continues to be used in 
women of childbearing age as several pregnancy registries have established the commonality of 
valproate to be prescribed (Roullet et al., 2013). Subsequently, valproate has clinical guidelines 





indicate that valproate should be avoided in pregnancy if possible due to the increased risks of 
congenital malformations (Werler et al., 2011). 
 This project intends to inform professional practice regarding the number of prescriptions 
for valproate prescribed to women of childbearing age. Additionally, it looks at how many of 
those women of childbearing are on pregnancy preventive programs or have a pregnancy given 
the fetal risks associated with valproate. This research is valuable as a consulting report to 
physician specialties such as psychiatry, neurology, and obstetrics. 
Aim 
To examine the number of women of childbearing age (18-44) who are prescribed valproate, 
some of their outcomes, and rates of pregnancy prevention to avoid risks as a result of prenatal 
valproate exposure. 
Under this aim, this project intends to answer the following research questions: 
• Question 1: At what rate is valproate being prescribed to women of childbearing age? 
• Question 2: What are the most common diagnoses (e.g., bipolar, epilepsy, migraines).  
• Question 3: For what age group of women is valproate most commonly prescribed?  
• Question 4: How many of those women prescribed valproate were part of a pregnancy 
prevention program? 
• Question 5: Of those women taking valproate, how many later experienced a pregnancy? 
Study Importance 
 As the risks to children of mothers exposed to AEDs have been increasingly understood, 
the warnings against such medications have been strengthened. Specifically, there has been an 





of valproate (Sawhney et al., 2019). Worldwide there is an agreement that valproate is a serious 
teratogen. However, there is still no agreement on proper guidelines for women who may 

























 Until recently, there were very little data on the effects of antiepileptic drug (AED) 
exposure in utero. However, in the past two decades, data from several prospective pregnancy 
registries have significantly increased the understanding of the critical risks for major congenital 
malformations associated with several AEDs (Gerard & Meador, 2015). This chapter examines 
the risks associated with valproate among women of childbearing age and the risks valproate 
poses for a child through maternal exposure. The chapter primarily looks at valproate in the 
context of its therapeutic use for epilepsy, as research into its teratogenic properties is limited 
outside of this field.  
Valproate as a Therapeutic 
 Valproate, classified as an anticonvulsant or AED, has several modalities. The 
pharmaceutical is available as an extended-release formulation in capsule form, as a delayed-
release formulation in tablet form, a sprinkle capsule, or syrup (AHFS, 2020). Valproate was first 
introduced for human use in 1967 in Europe, and its use was licensed in the United Kingdom in 
1975. It was not until 1978 that it became clinically available in the United States as an 
immediate-release formulation and then again in 1983 as alternative formulations (Adab et al., 
2004). 
 The U.S. Food and Drug Administration (FDA) initially approved valproate to treat 
seizures, but some valproate products are also approved to treat other ailments. Valproate is 
widely popular for its broad range of anticonvulsant effects and that it also has limited sedative 





it is recognized as one of the most critical AEDs for its wide spectrum effectiveness and is most 
notable in the acute treatment of bipolar disorder (Alsdorf & Wyszynski, 2005). Valproate 
products include valproate sodium, divalproex sodium, valproic acid, and other generics (FDA, 
2015). As a result, the term valproate was used to encompass the numerous varieties of the drug.  
  Valproate is a y-aminobutyric acid (GABA) agonist (Angus-Leppan & Liu, 2018; 
Wyszynski et al., 2005). Studies show enhanced GABA inhibition and the blockade of NMDA 
receptors impairs neurogenesis and cell migration, which in turn can lead to cortical dysplasia 
and reduced brain volume (Velez-Ruiz & Meador, 2015). Furthermore, valproate targets 
neurotransmitters, ion channels, and second messenger systems in the brain. This 
neurotransmitter medium in a developing brain plays a significant role in regulating neuronal 
differentiation and migration (Velez-Ruiz & Meador, 2015).  
Drug Uses 
 Valproate entered the market as a therapeutic intervention for absence seizures. Since 
then, its use has expanded to include the treatment of complex and partial seizures, as well as a 
preventative for migraines in some countries, a treatment for acute mania, and as a mood 
stabilizer for bipolar disorder (Macfarlane & Greenhalgh, 2018; Wyszynski et al., 2005). 
Similarly, in 2012, about 1.5 million individuals received valproate on an outpatient basis, to 
include 67% for psychiatric and mood disorders, 9% for migraines, and 9% for epilepsy in the 
United States (Angus-Leppan & Liu, 2018).  
  According to Macfarlane and Greenhalgh (2018), the drug's use for epilepsy continues to 
decline in the United Kingdom as the number of third-generation anticonvulsants increase; its 
use for bipolar disorder has been growing. Furthermore, this happens mostly among many 





were like those also seen in Ireland. More alarming, 20% of pregnant women with epilepsy were 
treated with valproate between 1999 to 2004. Subsequently, a more recent U.K. study revealed 
that valproate constituted 25% of all AED prescriptions in pregnancy (Macfarlane & 
Greenhalgh, 2018). 
Valproate Transmission 
 Valproate is said to cross the placenta and present a higher concentration in the child than 
in the mother (Alsdorf & Wyszynski, 2005). Consequently, valproate is known to induce 
apoptosis, a programmed cell death typically occurring in early development to eliminate 
unwanted cells (NIH, n.d.; Velez-Ruiz & Meador, 2015).  
Teratogenic Properties 
 Valproate is associated with a significant risk increase for teratogenesis, production of 
malformations in a child, compared to the baseline population rates and other ordinary AEDs for 
over 30 years of clinical studies (Gerard & Meador, 2015; Jentink et al., 2010). In a 1983 
Morbidity and Mortality Weekly Report from the CDC, valproate was stated to be a new cause of 
congenital malformations (CDC, 1983). The report found a significant association between 
valproate exposure during the first trimester of pregnancy and spina bifida and concluded that 
valproate should be considered a human teratogen (CDC, 1983). Since then, many factors are 
said to contribute to the teratogenic properties. Some of these factors include drug dosage, 
gestational age of the child at the time of the exposure, and differences in metabolism between 
the mother and child (Alsdorf & Wyszynski, 2005).   
 Valproate's teratogenic properties have since been evidenced by clinical studies such as 
those done by Weston et al. (2016), Christensen et al. (2013), and Eriksson et al. (2005). In 





teratogenic properties (Alsdorf & Wyszynski, 2005; Tomson et al., 2011). Furthermore, across 
several of these human studies, valproate has been the most highly associated with cognitive and 
behavioral teratogenesis of all AEDs (Gerard & Meador, 2015). In the end, clinical research has 
identified many risks associated with the drug that include those congenital malformations, 
developmental delays, reduced cognitive function, and, most recently, autism (Roullet et al., 
2013). 
 Dose-Dependent Risks 
 Although it can be considered generally unsafe for mothers and their developing fetuses, 
valproate has dose-dependent teratogenic risks (Virta et al., 2018). Although risks are still 
prevalent, most studies suggest that the chances for major congenital malformations begin to 
increase significantly at doses of 600 mg a day and become more prominent at doses above 
1,000 mg per day (Koren et al., 2006). Many researchers agree that valproate use creates an 
increased risk for those significant congenital malformations, especially in doses over 1,000 mg 
per day (Alsdorf & Wyszynski, 2005). Furthermore, apoptosis inducement, as previously 
discussed, begins to occur at levels below the therapeutic range (Velez-Ruiz & Meador, 2015). 
The standard therapeutic valproate doses range from 200 mg to 3,600 mg per day (Roullet et al., 
2013).  
 Additionally, a study by Tomson et al. (2011) examined significant congenital 
malformations of children up to 1 year in age. These data came from the EURAP pregnancy 
registry and focused on children exposed to four of the most common AEDs, one of which was 
valproate. The authors aimed to establish the risks of major congenital malformations after 
monotherapy exposure. This study showed that dose contributed to the risk of congenital 





increased incidence of congenital malformations. The researchers assessed the pregnancy 
outcomes according to the dose taken at the time of conception, despite any subsequent dose 
changes (Tomson et al., 2011).  
 Subsequently, Mawhinney et al. (2012) used the U.K. Epilepsy and Pregnancy Register 
to extract data for those pregnancies that were exposed to valproate. They calculated 
malformation rates and relative risks as a function of the valproate exposure focusing on all 
pregnancies exposed solely to valproate during the first trimester (Mawhinney et al., 2012). They 
found a significant dose-response with an almost doubling of the risk for those exposed to more 
than 1000 mg a day compared to those on less than 1000 mg a day (Mawhinney et al., 2012).  
 Moreover, a retrospective study of children born to mothers with epilepsy found that 
doses above 800 mg were associated with 8-15-point lower verbal IQ Valproate exposure was 
associated with additional education needs (AEN), as 19.7% of the sample had received speech 
therapy at some point (Adab et al., 2004). Further, Gedzelman & Meador (2012) found that 
valproate exposure also appears to have a dose-dependent IQ impact, with the effects being more 
significant on verbal than non-verbal IQ abilities (Gedzelman & Meador, 2012).  
Polytherapy Versus Monotherapy 
 In addition to dose, valproate is also used as either a form of monotherapy or 
polytherapy, meaning two or more treatments. Research shows that children with prenatal 
polytherapy exposure have worse cognitive and behavioral outcomes versus those children 
exposed to monotherapy or unexposed to valproate, whereby there is an increased risk of defects 






  In a preliminary retrospective study by Adab et al. (2001), a comparison was drawn 
between the proportion of school-age children exposed to different drug regimens and those who 
had AENs with or without physical disability born to mothers with epilepsy. They found that 
exposure to polytherapy, including valproate, was highly associated with AENs compared to 
both those who were unexposed and those who were exposed to polytherapy excluding valproate 
(Adab et al., 2001).  
 Adab et al. (2001) found that one of the most common monotherapy exposures (37.3%) 
for school-age children was valproate in utero. The polytherapy regimens often vary, but 
valproate combined with another AED is one of the most common polytherapy forms. Of the 
women taking AEDs at the time of pregnancy, over two-thirds were on monotherapy, and most 
of those were on valproate (Adab et al., 2001). Additionally, data for specific drug regimens 
showed that much of the risks for AENs among those exposed to monotherapy or polytherapy 
might be accounted for by valproate exposure. Thirty percent of those exposed to valproate 
monotherapy in utero had AENs, compared to 3.2% and 6.5% of those exposed to other AEDs 
studied (Adab et al., 2001).  
Rodent Studies 
 Behavioral studies of mice and rat offspring are the most used model in human disease 
research to provide insight into the mechanisms underlying many diseases. They are used to 
explore the efficacy of drugs and predict patient responses (Justice, 2016). There are reports of 
valproate teratogenicity in animals since the 1970s and in humans since the 1980s, whereby 
mouse and rat animal studies have examined anatomical, behavioral, molecular, and 
physiological outcomes of in utero exposure to valproate (Angus-Leppan & Liu, 2018; Roullet et 





 Notably, these animal studies have shown that the timing of exposure affects the type of 
identified malformations. For example, valproate exposure during the first trimester of gestation 
results in malformations of major organs. By contrast, exposure later in pregnancy results in an 
increased risk of neurodevelopmental defects when brain cells proliferate and migrate (Alsdorf & 
Wyszynski, 2005). Additionally, animal studies examining valproate have recently shown 
autistic-like outcomes, including social behavior deficits, increased repetitive behaviors, and 
communication deficits (Roullet et al., 2013). 
 Furthermore, animal studies have suggested that AED-induced apoptosis alters the 
neurotransmitter environment while impairing synaptogenesis, or the formation of synapses in 
the nervous system. Moreover, impaired synaptogenesis is one of the mechanisms responsible 
for cognitive and behavioral teratogenesis (Velez-Ruiz & Meador, 2015).  
Valproate and Pregnancy 
 Today, an increasing number of pregnant women continue to be exposed to valproate, 
despite its use during the first trimester being associated with an increased risk of spina bifida 
(Jentink et al., 2010; Koren, 2006). Adab et al. (2001) say that roughly one-third of all people 
receiving AEDs were women of childbearing age in 2001. In addition, 1 in 250 pregnancies was 
exposed to AEDs whereby over one million women with epilepsy in the United States were of 
childbearing age, and three to five births per 1,000 were to those women in 2015 (Adab et al., 
2001). Velez-Ruiz & Meador, 2015). Additionally, it was estimated that 1.5 million individuals 
were prescribed valproate, in 2012 and roughly 22% of those were women of childbearing age 
(Angus-Leppan. & Liu, 2018). The total number of children exposed to AEDs, including 
valproate, however, is likely to be more noteworthy due to their use as treatments for other 





Identification of the Risks Associated with Valproate Exposure 
 Not long after valproate was introduced for clinical use in epilepsy, emerging cases 
suggested those increased risk of neural tube defects, including spina bifida (Koren et al., 2006; 
Jentink et al., 2010). Today, although risk estimations associated with valproate vary, there may 
be as much as a two- to three-fold risk increase in congenital malformations among babies born 
to women with epilepsy on valproate compared to the general population (Adab et al., 2001).   
 To determine the risks of major congenital malformations for children exposed to AEDs 
in utero, the U.K. Epilepsy and Pregnancy Register was established (Mawhinney et al., 2012). 
According to the organization's website, the register began in 1996 for mothers who take one or 
more AED to prevent seizures. The organization's main objective is to obtain information on the 
occurrence of significant malformations they then publish. Furthermore, to identify the risks 
posed by valproate and other AEDs, the EURAP Epilepsy and Pregnancy Registry is an 
observational cohort study representing physicians from 45 countries, including Europe, Asia, 
Latin America, and Africa. According to the most recent figures, this registry was established in 
1999 and had more than 700 collaborators (EURAP, 2018; Tomson et al., 2011).   
Structural Malformations 
 Valproate has been associated with a number of structural malformations in developing 
children, including Spina Bifida. A 1982 study established a 20-fold increase in the risk for the 
occurrence of spina bifida associated with valproate during pregnancy (Wyszynski et al., 2005). 
A communicative Morbidity and Mortality Weekly Report by the CDC (1983) found that two 
were exposed to valproate among 118 infants with spina bifida. In a group of other 





pregnant woman in the United States, treated with valproate, would have a 1-2% chance of 
having a child with spina bifida (CDC, 1983).   
 To add further evidence of the drug's teratogenicity, the Morbidity and Mortality Weekly 
Report (1983) also referenced a U.K. researcher who concluded that, of infants born to 196 
women treated with valproate, nine had spina bifida, and 30 had other structural defects that 
included cardiovascular defects, orofacial clefts, and abnormalities of the fingers or toes (CDC, 
1983). Despite these previous reports, as of 2001, only neural tube defects were explicitly linked 
with valproate, which had the risk for spina bifida as high as 5% (Adab, Jacoby, Smith, & 
Chadwick, 2001; Wyszynski et al., 2005). 
 Likewise, a prospective study looked at the rate of significant malformations identified at 
birth from mothers who had taken valproate during pregnancy and were enrolled in the North 
American Antiepileptic Drug Pregnancy Registry, a surveillance registry system for pregnant 
women exposed to anticonvulsant drugs. For this study, medical records were obtained regarding 
the mother's medical history and any malformations identified in the child (Wyszynski et al., 
2005). The researchers studied 3,441 women enrolled in the pregnancy registry between 
February 1, 1997, and November 20, 2003. Valproate was taken by 235 of those women for 
epileptic seizures. In children from this exposed group of women, 16 infants were confirmed as 
having significant malformations—a four-fold increase in risk for the women taking valproate 
over other drugs (Wyszynski et al., 2005). 
 Additionally, Koren et al. (2006) selected controlled cohort studies searching several 
databases that reported valproate use during the first trimester of pregnancy. They selected 
studies that had comparison groups of women treated with other antiepileptic drugs, untreated 





women. After reviewing more than 1,700 exposed infants reported throughout 11 cohort studies, 
researchers found that women who took valproate during the time in which the embryo develops 
had more than 2.5 times the risk of having a child with malformations above other AEDs. They 
also found that using valproate during pregnancy was shown to have a three-fold increase in 
major congenital malformations compared to the general population not exposed to AEDs 
(Koren et al., 2006).  
 Furthermore, Jentink et al. (2010) found in their review of published cohort studies that 
there were 14 significant malformations more commonly associated with valproate through 
various antiepileptic databases. There was a major congenital malformation observed in 118 of 
1,565 pregnancies. For these malformations, the risk appeared to be significantly higher with the 
association of exposure to valproate during the first trimester of pregnancy compared to those 
with no exposure to antiepileptic drugs during the first trimester (Jentink et al., 2010). The 
researchers then tested this information in a large population-based case-control study. They 
found significant associations between exposure to valproate monotherapy in the first trimester 
in six conditions: spina bifida, atrial septal defect, cleft palate, hypospadias, polydactyly, and 
craniosynostosis. They found that the risks for five of the conditions were two to seven times 
higher for exposed children. Specifically, the risk for spina bifida was as much as 16 times 
higher for exposed children depending on the control group used. Researchers also found an 
association between limb defects and exposure to valproate compared to other drugs used as an 
antiepileptic (Jentink et al., 2010).  
 Later, Werler et al. (2011) evaluated the use of specific antiepileptic drugs in pregnancy 
and their relationship with congenital malformations. They used data from the National Birth 





assessed the use of these drugs and the risks posed for neural tube defects, oral clefts, heart 
defects, hypospadias, a defect in male genitals, and other significant congenital disabilities 
(CDC, 2019a; Werler et al., 2011). The authors found that increased risks that were drug-specific 
were observed for valproate. These risks were associated with neural tube defects, oral clefts, 
heart defects, and hypospadias. For example, mothers exposed to valproate were 9.7 times more 
likely to have a child with a neural tube defect, 4.4 times more likely to have a child with an oral 
cleft, 2.0 times more likely to have a heart defect, and 2.4 times more likely to have hypospadias 
(Werler et al., 2011).   
  Lastly, Weston et al. (2016) assessed the effects of prenatal exposure to AEDs on the 
prevalence of congenital malformations using several sources, including the Cochrane Epilepsy 
Group Specialized Register and Medline. Prospective cohort studies, cohort studies set within 
pregnancy registries, and randomized controlled trials were used. Fifty studies were included, 
with 31 contributing to the meta-analysis (Weston et al., 2016). The researchers found that 
children exposed to valproate had the highest malformation risk levels than other AED. Children 
exposed to valproate also had a higher risk than both groups of children in the control group 
versus children exposed to the other AEDs whereby the level of malformation risk was linked to 
the amount or dose of valproate that the child was exposed to in utero (Weston et al., 2016).  
Fetal Valproate Syndrome 
 In 1984, Fetal Valproate Syndrome first started being used to describe the prominent 
malformations observed in children exposed to valproate in utero. This term refers to a collection 
of minor and major malformations occurring in exposed children, often consisting of facial 
malformations, including a flat nasal bridge, small upturned nose, and thin upper lip, as well as 





Moreover, no test can confirm a diagnosis of Fetal Valproate Syndrome. Other possible causes of 
the signs and symptomology must be ruled out first. However, Fetal Valproate Syndrome is often 
suspected in an infant with one or more of the signs and symptoms associated should the mother 
report having taken valproate during pregnancy (NIH, 2017).  
 Treatment for Fetal Valproate Syndrome is based on the signs and symptoms present in 
each child as management often involves a team of medical specialists (NIH, 2017). Moreover, 
parents of children born with Fetal Valproate Syndrome express grief and anger over delays in 
recognizing the problem, delays in diagnosis, and inadequate support for those with lifelong 
disabilities (Angus-Leppan, & Liu, 2018). 
Cognitive Malformations 
 Valproate also causes severe malformations that primarily affect the brain and spinal 
cord, causing lower intelligence and other cognitive malformations. The low intellectual ability 
is seen in 30% to 40% of children born to mothers who took valproate (AHFS, 2020; Sawhney et 
al., 2019).  
IQ Reductions 
 Exposure to valproate affects a child's development during pregnancy with a significant 
IQ reduction compared to children exposed to other AEDs. The IQ reductions (8-11 points 
lower) are considered substantial enough to affect their education and affect them later in life 
when entering the workforce (Tomson et al., 2015).  
 A meta-analysis of three studies, composed of 67 children exposed to the drug, calculated 
that fetal valproate exposure was associated with a six-point decrease in full-scale IQ (Gerard & 





functions of school-aged children aged six and below exposed to valproate in utero were 
examined through a population-based, controlled study that consisted of 28 children. They found 
that low intelligence prevalence with valproate exposure was 19%, while exceptionally low 
intelligence was 10% in the valproate exposed children (Eriksson et al., 2005). 
 Furthermore, an FDA Drug Safety Communication (2011) warned the public that a 
mother's valproate use during pregnancy heightens her risk of having children born with lowered 
cognitive test scores. Furthermore, the Drug Safety Communication (2011) outlined initial 
cognitive test scores performed on children at age 3 with supportive studies of cognitive tests 
performed on children ages 5 to 16, with the most extensive research being a prospective cohort 
study conducted in the United States and the United Kingdom. However, the communication 
concluded that the long-term effects and whether the impact on cognitive development occurs 
when the child's exposure does not span the entirety of pregnancy are unknown (FDA, 2011).    
Developmental Delays 
 Children exposed to valproate in utero have a delay in achieving developmental 
milestones, particularly verbal skills. This delay includes communication problems, including 
talking, poor language skills. Additionally, valproate also can cause coordination problems, 
including walking and learning problems affecting memory, emotions, and behavior (AHFS, 
2020; Gerard & Meador, 2015; Sawhney et al., 2019). 
 To study the cognitive effects of valproate, Meador et al. (2009) used a cohort consisting 
of 258 children, 53 of which were exposed to valproate. As part of the Neurodevelopmental 
Effects of Antiepileptic Drugs study enrolling pregnant women who used AEDs from October 
1999 through February 2004 in 25 epilepsy centers in the United States and the United Kingdom, 





included increased developmental delays in children younger than 6 years of age, increased 
special education needs in children 5 to 18 years of age, and reduced verbal IQ in children 6 to 
16 years of age, compared to unexposed children (Meador et al., 2009). 
Autism 
 Recently it has been found that children exposed to valproate are more likely to 
demonstrate poor adaptive skills and a heightened risk for neurodevelopmental disorders, 
including attention deficit hyperactivity disorder and autism (Gerard & Meador, 2015). Evidence 
supports this link between cognitive function and the increased risk of autism with valproate 
exposure, thereby stressing the importance of understanding how the drug impacts a child's 
neurodevelopment (Roullet et al., 2013).  
 Clinical studies show valproate exposure in the first trimester of pregnancy is associated 
with a higher child incidence of autism. This association is based initially on the increased 
frequency of autistic symptoms of children diagnosed with Fetal Valproate Syndrome despite the 
number of studies reporting the prevalence of autism following valproate exposure being limited 
(Roullet et al., 2013). Supporting this, Christensen et al. (2013) conducted a population-based 
cohort study evaluating the risk of autism in children exposed to valproate prenatally in 
Denmark. They found a higher risk of autism spectrum disorder and childhood autism among 
children of women who used valproate during pregnancy. The risks were also higher than those 
for children whose mothers were previously valproate users but stopped at least 30 days before 
conception (Christensen et al., 2013).  
History of Guidelines 
 Of all the AEDs available, the use of valproate during childbearing years and pregnancy 





during pregnancy have emphasized the need for reassessment in its use clinically during these 
years (Roullet et al., 2013). Hence, despite its known risks, valproate continues to be used in 
women of childbearing age as several pregnancy registries have established the commonality of 
valproate to be prescribed (Roullet et al., 2013). Subsequently, valproate has clinical guidelines 
for practitioners that suggest that it should be avoided during pregnancy. These guidelines 
indicate that valproate should be avoided in pregnancy if possible due to the increased risks of 
congenital malformations (Werler et al., 2011). 
 Supporting these claims, according to Jentink et al. (2010), the American Academy of 
Neurology recommended that valproate also be avoided during pregnancy, if possible. However, 
it might be challenging to avoid valproate provided reasonable seizure control (Jentink et al., 
2010). Additionally, building on those previous dose-dependence claims, doses of more than 
1,000 mg per day should be avoided entirely when there is a likelihood of pregnancy (Mawer et 
al., 2002). 
 Moreover, the FDA warned that women of childbearing age deciding to take valproate 
should use adequate birth control precautions while taking the medications. The FDA also 
advised healthcare professionals to inform women of childbearing age of the increased risks 
associated with this drug. They should also continue to counsel women that valproate carries an 
increased risk of major malformations when used during pregnancy (FDA, 2011). 
 More recently, the FDA released a drug safety communication advising healthcare 
professionals and women that pregnant women should not take valproate to prevent migraine 
headaches. This was based on recent studies that suggest that these medications can cause 





 Most recently, the AHFS Patient Medication Information in the United States concluded 
that women of childbearing age not using effective birth control methods or pregnant women 
must not take valproate for migraine headache prevention, and pregnant women should only take 
valproate to treat seizures or bipolar disorder if other medications have not successfully 
controlled the symptoms or other drugs cannot be used. If valproate is being used, one must use 
effective birth control throughout treatment (AHFS, 2020).  
 Additionally, in the United Kingdom, a national alert was issued in 2018. The U.K. 
Medicines and Healthcare Products Regulatory Agency advised that valproate was not 
recommended in women of childbearing age unless other treatments have been ineffective at 
managing the symptoms or cannot be tolerated. When alternatives are not possible, there should 
also be a pregnancy prevention program in place. This strengthened regulation and included new 
advisement for the use of valproate in pregnancy for bipolar disorder. The advisement is that, 
should a woman with bipolar disorder become pregnant, the valproate treatment must be 
discontinued or changed to a treatment alternative (Sawhney et al., 2019). This new guidance 
required that practitioners be obligated to identify all women within their practice receiving 
valproate and arrange a prompt review of their contraceptive measures. They were also required 
to be referred to a specialist to have annual reviews (Sawhney et al., 2019). 
  Some additional imposed rulings addressing the defects are as follows (Angus-Leppan & 
Liu, 2018; Macfarlane & Greenhalgh, 2018; Virta et al., 2018). 
• In 2014, the New Zealand Medicines and Medical Devices Safety Authority said that 
valproate should not be used in women of childbearing potential unless other treatments 





• In 2014, documented teratogenic effects of valproate prompted restrictions in Finland of 
its use in females of childbearing age.  
• In 2016, the UK Royal College of Obstetricians and Gynecologists recommended 
avoiding prescribing this drug to any childbearing age women.  
• In 2016, the United States' stance was that its use might be acceptable should other 
medications not control the symptoms for which it is prescribed for epilepsy and bipolar. 
The risk for pregnant women outweighs any possible benefit for migraines.  
• In 2017, the French National Agency for the Safety of Medicines and Health Products 
(ANSM) imposed a nationwide ban against valproate in pregnancy due to the teratogenic 
risks  
• In 2018. the European Medicines Agency's Pharmacovigilance Risk Assessment 
Committee ruled that valproate must not be used in pregnancy unless there is a pregnancy 
prevention program in place.  
 Finally, the FDA indicated that stronger warnings about its use during pregnancy would 
be added to the drug labels and valproate's pregnancy category for migraine use would be 
changed from a "D," meaning the potential benefit of the drug in pregnant women may be 
acceptable despite the potential risks, to an "X," meaning that the risk of use in pregnant women 
outweighs any possible benefit (FDA, 2013). This is concluding that for use in pregnant women 
with epilepsy or bipolar, valproate should only be prescribed if other medications are not 
effective in treating the condition or are otherwise unacceptable for their condition. However, 
valproate products remain in the pregnancy category "D" for treating epilepsy and manic 
episodes associated with bipolar disorder (FDA, 2013). Regarding women of childbearing age 





to the management of the woman's medical condition. Non-pregnant women of childbearing age 
should use effective birth control (FDA, 2013).  
The Stance of Advocacy Groups 
 Consensus is growing to reduce the number of women taking valproate. This momentum 
comes from patient support groups, healthcare professionals, and the media. Expert advisory 
groups have limited responses, and regulations have varied. Reactions have ranged from those 
advocating shared decision making and informed patient choice to barring the use in pregnancy 
coupled with a pregnancy prevention program in those still taking the drug (Angus-Leppan, & 
Liu, 2018). Advocacy groups have suggested that the government, industry, and medical 
responses are too slow (Angus-Leppan, & Liu, 2018).   
 Some groups even propose a total ban on valproate as the only way to avoid future 
problems. The fundamental assumption behind those who want the drug banned is that valproate 
risks are so high for children that informed consent for the drug in pregnant women is not 
sufficient. A complete ban on the use during pregnancy would imply that a pregnancy prevention 
program is enforced with any woman of childbearing age who still wishes to take the drug. This 
would include a negative pregnancy test before starting a treatment or as part of a regular review 
process (Angus-Leppan, & Liu, 2018). Lastly, many advocacy groups feel that practitioners 
should inform women of the increased risks of cognitive deficits associated with the use of 
valproate, especially in early pregnancy, and when avoidable, the drug should not be used for 
treatment in female patients of childbearing age (Koren et al., 2006; Tomson et al., 2015). 
 For instance, there are certain epilepsies where alternatives are either few or have been 





females of childbearing age. Discussions should be taken that evaluate the risk-benefit of 
treatment options (Tomson et al., 2015). 
Discussion of Previous Studies' Limitations 
 According to some researchers, previous studies' findings are limited by small samples of 
exposed women and often a retrospective study design (Alsdorf & Wyszynski, 2005; Tomson et 
al., 2011). However, limitations aside, extensive clinical research outlines the health risks 
associated with in utero exposure to valproate (Roullet et al., 2013). The majority of research has 
demonstrated a consistent association between valproate exposure and development delay, for 
example (Gerard & Meador, 2015). 
Conclusion 
 Due to the rapid introduction of new drugs, when and how the drugs are prescribed have 
changed dramatically. There is a need to develop satisfactory methods to examine the risks of 
both old and new AEDs as data suggests that valproate should not be used as a first-line 
antiepileptic drug in women of childbearing age since data shows that roughly half of all 
pregnancies are unplanned (Adab et al., 2001; CDC, 2019b, Meador, 2009).  
 As the risks to children of mothers exposed to AEDs have been increasingly understood, 
the warnings against such medications have been strengthened. Specifically, there has been an 
increase in healthcare professionals and available patient resources regarding the acceptable use 
of valproate (Sawhney et al., 2019). Worldwide there is an agreement that valproate is a serious 
teratogen. However, there is still no agreement on proper guidelines for women who may 





 Given the risk associated with exposure during pregnancy, many advocates feel that 
valproate should be avoided, whenever possible, for epilepsy in women of childbearing age. 
When valproate is the most appropriate for treatment, advocacy groups say that the patient 
should be informed of the risks associated with valproate use during pregnancy, and all treatment 
alternatives and effective contraception, when relevant, should be ensured for those prescribed 
valproate (Sawhney, 2019). Furthermore, according to surveys in the United Kingdom, around 
half of epileptic women are unaware that valproate poses any risks to the child (Angus-Leppan & 
Liu, 2018; Macfarlane & Greenhalgh, 2018).  





















 This project intends to inform professional practice regarding the number of prescriptions 
for valproate prescribed to women of childbearing age. Additionally, it looks at how many of 
those women of childbearing are on pregnancy preventive programs or have a pregnancy given 
the fetal risks associated with valproate. This research is valuable as a consulting report to 
physician specialties such as psychiatry, neurology, and obstetrics. 
Aim 
To examine the number of women of childbearing age (18-44) who are prescribed valproate, 
some of their outcomes, and rates of pregnancy prevention to avoid risks resulting from prenatal 
valproate exposure. 
Under this aim, this project intends to answer the following research questions: 
• Question 1: At what rate is valproate being prescribed to women of childbearing age? 
• Question 2: What are the most common diagnoses (e.g., bipolar, epilepsy, migraines).  
• Question 3: For what age group of women is valproate most commonly prescribed?  
• Question 4: How many of those women prescribed valproate were part of a pregnancy 
prevention program? 
• Question 5: Of those women taking valproate, how many later experienced a pregnancy? 
Study Design 
 This study is a retrospective cohort study, the researcher followed the sample overtime 





research questions as part of an epidemiological case study design. The research sets to prove no 
causal relationship but merely describe the distribution between the defined variables.  
Population and Sample 
 The study sample is women of childbearing age, 18 to 44 years of age, based on the CDC 
indicator definition for reproductive health (CDC, 2015). Inclusion data includes women 
between the ages of 18 and 44 and those with three or more months of valproate prescription 
fills. Excluded women were those not between the ages of 18 and 44 and those who had less than 
three (3) months of valproate prescribed to them.  
• At what rate is valproate being prescribed to women of childbearing age? 
Mawhinney et al. (2012) excluded women from their study women who were missing data on 
drug dose and administration. Since this study is not concerned with dosage, there was no 
exclusion.  
• What are the most common prescribing diagnoses (e.g., bipolar, epilepsy, migraines)?  
Inclusion criteria included the three-common diagnosis (bipolar, epilepsy, and migraines). 
Exclusion criteria were women with those outside these diagnoses.  
• For what age group of women is valproate most prescribed?  
• How many of those women prescribed valproate were part of a pregnancy prevention 
program? 
Inclusion criteria included those women who have a billing code of Z30-Z30.9 within their 
billing history. Exclusion criteria consisted of any women who do not have a billing code within 





• How many of those women prescribed valproate were not part of a pregnancy prevention 
program? 
Inclusion criteria included those women who did not have a billing code of Z30-Z30.9 within 
their billing history. Exclusion criteria consisted of any women with the billing codes of Z30 to 
Z30.9 billing code within their billing data.  
• Of those women taking valproate, how many went on to experience pregnancy?  
Inclusion criteria included all pregnancies (Z33). Mawer et al. (2002) had no exclusions in their 
study but instead included every pregnancy known by women attending the clinic. Since we are 
not concerned with the viability of the pregnancies, all records were included. There were no 
exclusions.   
 The study population comes from the 2016-2018 MarketScan® Commercial dataset 
obtained by the Medical University of South Carolina. This dataset is a compiled set of 119 
million privately insured individuals' billing records. The data are de-identified and examined by 
the IRB at MUSC and deemed non-human subjects.   
Database 
 According to the White Paper for IBM MarketScan Research Databases for Health 
Services Researchers (2019), 
The IBM MarketScan® Commercial Database consists of medical and drug data from 
employers and health plans. It contains data for several million individuals annually, 
encompassing employees, their spouses, and dependents covered by employer-sponsored 





organizations (EPOs), POS plans, indemnity plans, HMOs, and consumer-directed health 
plans (CDHPs). 
This data is of value to the research because, as the White Paper (2019) continues,  
Medical claims are linked to outpatient prescription drug claims and person-level 
enrollment information. The MarketScan Commercial Database may offer a distinct 
advantage over other databases for research on medication use. As these data are primarily 
sourced from employers, claims for mail-order prescriptions and specialty pharmacies are 
also included. 
Definition of Variables 
 The control variable is birth control, whether oral pills, intrauterine devices, transdermal 
patches, or other identifiable methods. The researcher used the searchable ICD-10-CM grouping 
code of Z30 through Z30.9 for contraceptive management.  
 In the study, the researcher followed a subset of women prescribed valproate using the 
women's billing data looking for searchable valproate NDC groupings of 71930-057-12 (oral). 
Additionally, the researcher used the searchable ICD 10 group billing code of Z33 for pregnancy, 
the DSM code of Z37.x for delivery, and the ICD 10 codes for bipolar F31.9.x, epilepsy G40.x, 






Table 1. ICD-10-CM codes  
Description Codes 
Contraception Management Z30 – Z30.9 
Pregnancy  Z32-Z32.3 





Table 2. Study NDCs 
Description Route Codes 
DIVALPROEX SODIUM ORAL 0074-3826 
DIVALPROEX SODIUM  ORAL 0074-6114 
DIVALPROEX SODIUM  ORAL 0074-6212 
DIVALPROEX SODIUM ORAL 0074-6214 
DIVALPROEX SODIUM ORAL 0074-6215 
DIVALPROEX SODIUM  ORAL 0074-7126 
DIVALPROEX SODIUM  ORAL 0378-0472 
DIVALPROEX SODIUM ORAL 0378-0473 
DIVALPROEX SODIUM ORAL 0615-7949 
DIVALPROEX SODIUM ORAL 0615-7950 
DIVALPROEX SODIUM ORAL 0615-7956 





DIVALPROEX SODIUM ORAL 0615-8242 
DIVALPROEX SODIUM ORAL 0615-8326 
DIVALPROEX SODIUM ORAL 0615-8327 
DIVALPROEX SODIUM ORAL 0615-8328 
DIVALPROEX SODIUM ORAL 0615-8329 
DIVALPROEX SODIUM ORAL 0615-8330 
DIVALPROEX SODIUM ORAL 0781-2243 
DIVALPROEX SODIUM ORAL 0832-7122 
DIVALPROEX SODIUM ORAL 0832-7123 
DIVALPROEX SODIUM ORAL 0832-7124 
DIVALPROEX SODIUM ORAL 0904-6363 
DIVALPROEX SODIUM ORAL 0904-6364 
DIVALPROEX SODIUM ORAL 0904-6615 
DIVALPROEX SODIUM ORAL 0904-6860 
DIVALPROEX SODIUM ORAL 0904-6861 
DIVALPROEX SODIUM ORAL 10370-510 
DIVALPROEX SODIUM ORAL 10370-511 
DIVALPROEX SODIUM ORAL 16714-484 
DIVALPROEX SODIUM ORAL 16714-485 
DIVALPROEX SODIUM ORAL 17856-0109 
DIVALPROEX SODIUM ORAL 27241-115 
DIVALPROEX SODIUM ORAL 29300-138 





DIVALPROEX SODIUM ORAL 29300-140 
DIVALPROEX SODIUM ORAL 43063-295 
DIVALPROEX SODIUM ORAL 43353-547 
DIVALPROEX SODIUM ORAL 48433-125 
DIVALPROEX SODIUM ORAL 48433-126 
DIVALPROEX SODIUM ORAL 50090-2007 
DIVALPROEX SODIUM ORAL 50090-3416 
DIVALPROEX SODIUM ORAL 50090-3616 
DIVALPROEX SODIUM ORAL 50090-4187 
DIVALPROEX SODIUM ORAL 50090-4409 
DIVALPROEX SODIUM ORAL 50090-4737 
DIVALPROEX SODIUM ORAL 50090-4861 
DIVALPROEX SODIUM ORAL 50268-258 
DIVALPROEX SODIUM ORAL 51079-766 
DIVALPROEX SODIUM ORAL 51079-767 
DIVALPROEX SODIUM ORAL 51655-365 
DIVALPROEX SODIUM ORAL 55111-529 
DIVALPROEX SODIUM ORAL 55111-530 
DIVALPROEX SODIUM ORAL 55111-531 
DIVALPROEX SODIUM ORAL 55111-532 
DIVALPROEX SODIUM ORAL 55111-533 
DIVALPROEX SODIUM ORAL 55111-534 





DIVALPROEX SODIUM ORAL 55154-4759 
DIVALPROEX SODIUM ORAL 55154-7145 
DIVALPROEX SODIUM ORAL 55154-7640 
DIVALPROEX SODIUM ORAL 57237-047 
DIVALPROEX SODIUM ORAL 57237-048 
DIVALPROEX SODIUM ORAL 57237-106 
DIVALPROEX SODIUM ORAL 58118-0040 
DIVALPROEX SODIUM ORAL 60687-211 
 
VALPROIC ACID ORAL 0121-0675 
VALPROIC ACID ORAL 0121-1350 
VALPROIC ACID ORAL 0121-4675 
VALPROIC ACID ORAL 0527-5250 
VALPROIC ACID ORAL 0591-4012 
VALPROIC ACID ORAL 0615-8205 
VALPROIC ACID ORAL 0832-0310 
VALPROIC ACID ORAL 17856-0675 
VALPROIC ACID ORAL 17856-4012 
VALPROIC ACID ORAL 42291-844 
VALPROIC ACID ORAL 43353-085 
VALPROIC ACID ORAL 43353-107 





VALPROIC ACID ORAL 50383-792 
VALPROIC ACID ORAL 60429-246 
VALPROIC ACID ORAL 60432-621 
VALPROIC ACID ORAL 60687-262 
VALPROIC ACID ORAL 63629-7597 
VALPROIC ACID ORAL 63739-253 
VALPROIC ACID ORAL 67046-807 
VALPROIC ACID ORAL 67046-808 
VALPROIC ACID ORAL 68094-193 
VALPROIC ACID ORAL 68094-701 
VALPROIC ACID ORAL 69452-150 
VALPROIC ACID ORAL 70518-0079 
VALPROIC ACID ORAL 70518-1968 
VALPROIC ACID ORAL 70518-2215 
VALPROIC ACID ORAL 71930-057 











Figure 1. Study Flowchart 






 These data were analyzed using SAS version 9.4 (Cary, NC). Data is described using 
measures of central tendency (mean, median, mode) and dispersion (standard deviation, 
quartiles, min, max). The researcher seeks to describe and quantify the number of pregnancies in 
the dataset among women 18-44 years of age on valproate in this descriptive survey. Differences 
between those on birth control and those not on birth control were made using student’s t-test for 
normally distributed data, Wilcoxon-Mann-Whitney for non-normally distributed data, and chi-
squared tests for categorical data. Statistical significance has been defined a priori to be <0.05. 
Limitations 
 Factors that affected my findings included the length of contraceptive use and type of 
contraceptive use, such as condom use, which the study could not account for. The researcher 
studied only measurable pregnancy preventions (oral pills, intrauterine devices, transdermal 
patches) for this research.  Filtering this data did not increase the level of control for these 
factors. Additional limitations include the fact that there is no way to know whether a woman 
prescribed valproate ingested the oral medication, nor does the researcher match dates to verify 










CHAPTER IV  
ARTICLE MANUSCRIPT 
Introduction 
 Valproate entered the market as a therapeutic intervention for absence seizures. Since 
then, its use has expanded to include the treatment of complex and partial seizures, a 
preventative for migraines in some countries, a treatment for acute mania, and a mood stabilizer 
for bipolar disorder. 1,2 Today, an increasing number of pregnant women continue to be exposed 
to valproate, despite its use during the first trimester being associated with an increased risk of 
spina bifida. 3,4 Adab et al.5 say that roughly one-third of all people receiving Antiepileptic Drugs 
(AEDs) were women of childbearing age in 2001. In addition, 1 in 250 pregnancies was exposed 
to AEDs whereby, over one million women with epilepsy in the United States were of 
childbearing age, and three to five births per 1,000 were to those women in 2015.5 Additionally, 
it was estimated that 1.5 million individuals were prescribed valproate, in 2012 and roughly 22% 
of those were women of childbearing age. 6 The total number of children exposed in utero to 
AEDs, including valproate, however, is likely to be more noteworthy due to their use as 
treatments for other conditions. 7  
 Valproate is associated with a higher risk for teratogenesis, the production of 
malformations in a child, compared to the baseline population rates and other ordinary AEDs for 
over 30 years of clinical studies. 8, 3 There are reports of valproate teratogenicity, the capability 
to cause malformations, in animals since the 1970s. Additionally, teratogenicity has been 
reported in humans since the 1980s, whereby mouse and rat animal studies have examined 
anatomical, behavioral, molecular, and physiological outcomes of in utero exposure to valproate. 





 Notably, these animal studies have shown that the timing of exposure affects the type of 
identified malformations. For example, valproate exposure during the first trimester of gestation 
results in malformations of major organs. By contrast, exposure later in pregnancy results in an 
increased risk of neurodevelopmental defects when brain cells proliferate and migrate. 10 
Additionally, animal studies examining valproate have recently shown autistic-like outcomes, 
including social behavior deficits, increased repetitive behaviors, and communication deficits. 9  
 Valproate's teratogenic properties have been evidenced by clinical studies done by 
Weston 11, Christensen 12, and Eriksson 13. In addition, national and international pregnancy 
registries have increasingly identified AEDs' teratogenic properties. 10, 14 Furthermore, across 
several of these human studies, valproate has been the most highly associated with cognitive and 
behavioral teratogenesis of all AEDs. 8 In the end, clinical research has identified many risks 
associated with the drug that include those congenital malformations, developmental delays, 
reduced cognitive function, and, most recently, autism. 9  
 A prospective study looked at the rate of significant malformations identified at birth 
from mothers who had taken valproate during pregnancy and were enrolled in the North 
American Antiepileptic Drug Pregnancy Registry, a surveillance registry system for pregnant 
women exposed to anticonvulsant drugs. Medical records were obtained regarding the mother's 
medical history and any malformations identified in the child for this study. 15 The researchers 
studied 3,441women enrolled in the pregnancy registry between February 1, 1997, and 
November 20, 2003. Valproate was taken by 235 of those women for epileptic seizures. In 
children from this exposed group of women, 16 infants were confirmed as having significant 





 Additionally, Koren et al. 16 selected controlled cohort studies searching several 
databases that reported valproate use during the first trimester of pregnancy. They selected 
studies that had comparison groups of women treated with other antiepileptic drugs, untreated 
epileptic women, or healthy women that could represent the general population of pregnant 
women. After reviewing more than 1,700 exposed infants reported throughout 11 cohort studies, 
researchers found that women who took valproate during the time in which the embryo develops 
had more than 2.5 times the risk of having a child with malformations above other AEDs. They 
also found that using valproate during pregnancy was shown to have a three-fold increase in 
major congenital malformations compared to the general population not exposed to AEDs. 16  
 Furthermore, Jentink et al. 3 found in their review of published cohort studies that there 
were 14 significant malformations more commonly associated with valproate through various 
antiepileptic databases. There was a major congenital malformation observed in 118 of 1,565 
pregnancies. For these malformations, the risk appeared to be significantly higher with the 
association of exposure to valproate during the first trimester of pregnancy compared to those 
with no exposure to antiepileptic drugs during the first trimester. 3 The researchers then tested 
this information in a large population-based case-control study. They found significant 
associations between exposure to valproate monotherapy in the first trimester in six conditions: 
spina bifida, atrial septal defect, cleft palate, hypospadias, polydactyly, and craniosynostosis. 
They found that the risks for five of the conditions were two to seven times higher for exposed 
children. Specifically, the risk for spina bifida was as much as 16 times higher for exposed 
children depending on the control group used. Researchers also found an association between 





 Later, Werler 17 evaluated the use of specific antiepileptic drugs in pregnancy and their 
relationship with congenital malformations. They used data from the National Birth Defects 
Prevention Study, one of the most extensive studies on birth defects in the United States. They 
assessed the use of these drugs and the risks posed for neural tube defects, oral clefts, heart 
defects, hypospadias, a defect in male genitals, and other significant congenital disabilities. 18, 17 
The authors found that increased risks that were drug-specific were observed for valproate. 
These risks were associated with neural tube defects, oral clefts, heart defects, and hypospadias. 
For example, mothers exposed to valproate were 9.7 times more likely to have a child with a 
neural tube defect, 4.4 times more likely to have a child with an oral cleft, 2.0 times more likely 
to have a heart defect, and 2.4 times more likely to have hypospadias. 17    
  Lastly, Weston et al. 11 assessed the effects of prenatal exposure to AEDs on the 
prevalence of congenital malformations using several sources, including the Cochrane Epilepsy 
Group Specialized Register and Medline. Prospective cohort studies, cohort studies set within 
pregnancy registries, and randomized controlled trials were used. Fifty studies were included, 
with 31 contributing to the meta-analysis. 11 The researchers found that children exposed to 
valproate had the highest malformation risk levels than other AED. Children exposed to 
valproate also had a higher risk than both groups of children in the control group versus children 
exposed to the other AEDs. The malformation risk level was linked to the amount or dose of 
valproate that the child was exposed to in utero. 11  
Methods 
 This study is a retrospective cohort study. The researcher followed the sample 





specified research questions as part of an epidemiological design. The research set to prove no 
causal relationship but merely describe the distribution between the defined variables.  
 The study population came from the 2016-2018 MarketScan® Commercial Claims & 
Encounters dataset obtained by the Medical University of South Carolina. This dataset was a 
compiled set of 119 million privately insured individuals' billing records. The data were de-
identified and examined by the IRB at MUSC and deemed non-human subjects.   
Patients and Settings 
 The study sample was women of childbearing age, 18 to 44 years old, based on the CDC 
indicator definition for reproductive health. 19 Inclusion criteria included women with three or 
more months of valproate prescription fills. Exclusion criteria consisted of those not between 18 
and 44 and those who had less than three (3) months of valproate prescribed. Insurance 
information obtained from the MarketScan® data was 6 months pre-index and 12 months post-
index, whereby the data index was the date from which the first valproate prescription was filled.  
Aim 
 To examine the number of women of childbearing age (18-44) who were prescribed 
valproate, some of their outcomes, and rates of pregnancy prevention to avoid risks resulting 
from prenatal valproate exposure. 
Under the aim, the project intended to answer the following research questions: 
1) At what rate is valproate being prescribed to women of childbearing age? 
 Mawhinney 20 excluded women from their study who were missing data on drug dose and 





whereby the research examined all billing data for valproate within the pre and post-index of 
women ages 18-44.  
2) What are the most common prescribing diagnoses (e.g., bipolar, epilepsy, migraines)?  
 The research was only interested in the three common diagnoses (bipolar, epilepsy, and 
migraines) and therefore studied only the DSM-10 billing codes of F31.9 (bipolar), G40-G40.9 
(Epilepsy), and G43-G43.9 (migraines).  
3) For what age group of women is valproate most prescribed?  
 The research examined all billing data pertaining to women 18-44 years of age that fell 
within the pre and post-index.   
4) How many of those women prescribed valproate were part of a pregnancy prevention 
program? 
 This interest area included whether the women were partaking in a pregnancy prevention 
program as indicated by the ICD-10 CM codes of Z30-Z30.9 for contraceptive management 
within their billing history.  
5) Of those women taking valproate, how many later experienced a pregnancy?  
 For this area of interest, ICD-10 CM billing codes of Z32-Z32.3 were examined. Mawer 
21 had no exclusions in their study but instead included every pregnancy known by women 
attending the clinic. This study also used this logic. Of those pregnancies, the delivery outcome 






 These data were analyzed using SAS version 9.4 (Cary, NC). Data are described using 
measures of central tendency (mean, median, mode) and dispersion (standard deviation, 
quartiles, min, max). The research describes and quantifies the number of pregnancies among 
women 18-44 years of age on valproate in this epidemiological study. Tests for differences 
between those on birth control and those not on birth control were made using Student’s t-test for 
normally distributed data, Wilcoxon-Mann-Whitney for non-normally distributed data, and chi-
squared tests for categorical data. Statistical significance has been defined a priori to be <0.05. 
Results  
Table 3. Sample Characteristics 
 
Clinical characteristics 
Charlson comorbidity score 0.0 ± 0.0 
 
Elixhauser conditions  
Alcohol Abuse 2 (1.3) 
Blood Loss Anemia 1 (0.7) 
COPD 13 (8.7) 
Cardiac Arrhythmia 3 (2.0) 
Coagulopathy 2 (1.3) 
Deficiency Anemia 7 (4.7) 





Diabetes, Complicated 2 (1.3) 
Diabetes, Uncomplicated 5 (3.4) 
Drug Abuse 6 (4.0) 
Fluid/Electrolyte Disorder 2 (1.3) 
Hypertension, Uncomplicated 14 (9.4) 
Hypothyroidism 7 (4.7) 
Obesity 13 (8.7) 
Other Neurological Disorder 12 (8.1) 
Psychoses 4 (2.7) 
Pulmonary Circulation Disorder 1 (0.7) 
Rheumatoid Arthritis 4 (2.7) 
Weight Loss 3 (2.0) 
All values expressed as n (%) mean ±s.d., or median [Q1 - Q3] 
 
 The women examined for the study were primarily healthy, with the most notable 
characteristic being depression with n=23 (23.5%) of the sample. Other characteristics would not 
be classified as significant.  
 For research question 1: At what rate is valproate being prescribed to women of 
childbearing age, there were n=877 women aged 18-44 on valproate during 2016-2018. There 
was n=318 women across 3 years of MarketScan ® data prescribed 3 or more months of the 
drug. Of the 318 women, n=149 (46.8%) were analyzed for the study based on a 6-month pre-





Figure 2. Valproates Prescribed 
 
 For research question 2: What are the most common diagnoses (e.g., bipolar, epilepsy, 
migraines), it was found that n=102 (68.4%) of the n=149 women were prescribed valproate for 
one of the three diagnoses researched- there were no instances of multiple diagnoses within those 
examined. Of those diagnoses, the most commonly prescribed was as a therapeutic for migraines 
(n=50) followed by as a therapeutic for bipolar disorder (n=47).  
Table 4. Diagnosis 
 
Diagnosis Frequency (n=102) 
Bipolar 47 (31.5) 
Epilepsy 23 (15.4) 
Migraines 50 (33.6) 





Women of Child Bearing Age





Figure 3. Common Diagnoses 
 
 For research question 3: For what age group of women is valproate most commonly 
prescribed, the research showed that the average age for which valproate was prescribed was 34 
years of age (standard deviation of 7.4), and the median age was 36 years of age.  
Figure 4 Descriptive Statistics: Age of Women Represented in the Research 























Figure 5. Patient Age 
 
 For research question 4: How many of those women prescribed valproate were part of a 
pregnancy prevention program, the research showed that n=43 (28.9%) women were on one of 
the three forms of birth control investigated, with the most common form being an oral 
contraceptive (n=31). There was one billing ID that data showed was on both Depo and an IUD 
within the data set.  
Table 5. Contraceptives 
 
Contraceptive (Any) 43 (28.9) 
Contraceptive (Depo shot) 5 (3.4) 
Contraceptive (IUD) 8 (5.4) 
Contraceptive (Oral) 31 (20.8) 



























Figure 6. Contraceptive Use 
 
 For research question 5: Of those women taking valproate, how many went on to 
experience pregnancy, the research showed that of those women taking valproate, n=3 went on 
to experience a pregnancy while there was n=1 recorded birth out of the n=149 women.  
 
Table 6. Outcomes 
 
Pregnancy 3 (2.0) 
Birth 1 (0.7) 
All values expressed as n (%) 
  
Discussion 
 Of all the AEDs available, the use of valproate during childbearing years and pregnancy 













emphasized the need for reassessment in its use clinically during these years. 9 Hence, despite its 
known risks, valproate continues to be used in women of childbearing age as several pregnancy 
registries have established the commonality of valproate to be prescribed. 9  
 Furthermore, a consensus is growing to reduce the number of women taking valproate. 
This momentum comes from patient support groups and healthcare professionals based on the 
expert advisory groups’ limited responses and variations of regulations regarding the drug’s use. 
There are also mixed reactions among advocates, with reactions ranging from those advocating 
shared decision making and informed patient choice to those advocating to bar the drug’s use in 
pregnancy unless coupled with a pregnancy prevention program in those still taking the drug. 6  
 Moreover, the FDA's most recent guidance declares that valproate should not be 
administered to women of childbearing age unless other medications have failed to provide 
adequate symptom relief or are otherwise unacceptable. They continue by saying that in these 
situations, effective contraception should be used. Ultimately there is no change from their 
previous guidance in 2013.22. Notably, the research showed that 46.8% of the 318 women 
prescribed valproate were of childbearing age and were prescribed 3 or more months of 
valproate, whereby n=105 (70. 5%) of the sample were not on 1 of the 3 most common 
contraceptive methods.  
 Equally important is a recent study by Tachibana et al.23, who investigated patterns in 
psychiatrists’ prescriptions of valproate for bipolar female patients of childbearing age in Japan. 
The reason for doing so was based on the global procedures that state valproate should not be 
used for women of childbearing age. In this research, 571 psychiatrists responded to the survey, 
with approximately 70% answering that they frequently or occasionally prescribed valproate for 





commonly prescribed for migraines followed by bipolar disorder. This despite research on the 
effects of the drug being primarily focused on valproate as a therapeutic for epilepsy.   
 Meanwhile, the reason for the continued prescribing of valproate products is not yet 
apparent.24 One possible explanation could be that the risks associated with prescribing valproate 
have mainly been researched and limited to the epilepsy community, as mentioned previously, 
with neurologists primarily reading this research. 24 Psychiatric journals, for instance, contain 
only sporadic articles that may address the issue. Additionally, another main problem is that 
guidelines lack a set of mandatory and required rules. For example, some guidelines call for 
discussing the associated risks with those prescribed while paying attention to contraceptive use. 
In contrast, others mention the guidance that valproate should not be used in women of 
childbearing age unless other options have proven unsuitable and there is a contraception plan in 
place. Ultimately, most of those guidelines associated with fetal risks focus solely on treating 
women with epilepsy with the lack of awareness among psychiatrists and other practitioners.24  
 In conclusion, this research's findings highlight the importance of further education on 
the risks of valproate and women of childbearing age. This is based on the lack of studies 
focusing on the risks and prescribing patterns outside of the epilepsy community. Limitations to 
the research included the length of contraceptive use and type of contraceptive use, such as 
condom use, which the study could not account for. Ultimately, the researcher studied only 
measurable pregnancy preventions (oral pills, intrauterine devices, transdermal patches) for this 
research.  Filtering this data did not increase the level of control for these factors. Furthermore, 
future research could explore different funding streams as our research focused on commercial 
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A: Contraceptives Studied 
Description National Drug Code (NDC) 
Depo Shot 00009024802, 00009062601, 00009737611, 50090045900, 
50090066500, 54868334801, 00009074630, 00009074635, 
54569370100, 54569490400, 54569552700, 54868361300, 
54868410000, 54868410001, 00009470913, 54569621900, 
00548540000, 00548540025, 00548570100, 00703680101, 
00703680104, 50090088300, 50090332800, 54569561600, 
54569677100, 54868525700, 59762453701, 59762453702, 
59762453802, 62756009040, 62756009045, 67457088700, 
67457088701, 67457088799, 71205011801, 00548541000, 
00548541025, 00548571100 
Oral Contraceptive 00046257512, 51862023803, 52544095931, 54868491100, 
76388028301, 00555905167, 00555905179, 51862007201, 
51862007206, 52544094028, 00378729653, 00555905058, 
00555905079, 54569582600, 54868474200, 00603751201, 
00603751217, 00603751249, 51285012058, 54868473100, 
00555904358, 00555904379, 50090248100, 54868475400, 
50102015401, 50102015403, 50102025421, 50102025423, 
00052026108, 54868386300, 00378728253, 00378728285, 
16714036701, 16714036704, 00254203373, 00254203380, 





68180088211, 68180088213, 68180089111, 68180089113, 
68180089171, 68180089173, 00781406615, 70700011384, 
70700011385, 16714046401, 16714046404, 65862088728, 
65862088788, 54868270100, 00093330416, 00093330428, 
52544095428, 53217012728, 54569603200, 50419040901, 
50419040903, 54868618300, 54868582800, 50419040701, 
50419040703, 00781407515, 68180089411, 68180089413, 
52544029831, 52544029841, 00378729953, 00378729985, 
00378730053, 50090249400, 50090259400, 54569668800, 
54569668900, 59746076342, 59746076343, 60505418301, 
60505418303, 68180090211, 68180090213, 68462072029, 
68462072084, 68462073329, 68462073384, 71205014428, 
00093542328, 00093542358, 00093542362, 54569627200, 
54868616200, 50102024021, 50102024023, 59651002928, 
59651002988, 00781565615, 70700011484, 70700011485, 
54569662200, 68180088611, 68180088613, 68180088671, 
68180088673, 00555913167, 00555913179, 05559013179, 
54569612800, 54868592200, 00781565815, 70700011584, 
70700011585, 52544098228, 52544098231, 54569657600, 
50419040201, 50419040203, 54569534900, 54868459000, 
50419040501, 50419040503, 54569614400, 51862003603, 
52544098131, 54569643400, 59651003028, 59651003085, 





00378730785, 00555906458, 00555906479, 50090219100, 
54569662400, 54868594200, 00093807316, 00093807328, 
51862026001, 51862026006, 52544038328, 54569481700, 
54868424000, 52544038428, 54868477800, 52544029528, 
68462063729, 68462063784, 00905027721, 00905027928, 
54868051800, 00905029128, 00555904758, 54868486000, 
16714034001, 16714034002, 16714034004, 50090250500, 
54569669000, 68180085711, 68180085713, 00603762517, 
00603762549, 54569643600, 54868332800, 51862051006, 
52544029128, 54569511500, 54868423900, 75854060202, 
75854060203, 75854060228, 75854060101, 65862084928, 
65862084988, 00781558315, 70700011684, 70700011685, 
50102012001, 50102012003, 50102012010, 50102012048, 
50102022021, 50102022023, 00555904558, 00555904579, 
54868535600, 63187088928, 65862084828, 65862084888, 
50102013001, 50102013003, 50102013010, 50102013048, 
50102023021, 50102023023, 51660057286, 00378728753, 
00378729853, 54569668600, 68180085411, 68180085413, 
68180085471, 68180085473, 16714035901, 16714035903, 
16714035904, 00781558436, 70700011787, 00555912366, 
54868604400, 68180084411, 68180084413, 69238153106, 
00555901467, 00555901479, 50419041112, 54868436800, 





68180084313, 68462067291, 68462067295, 51862009701, 
51862009706, 52544027928, 54569499700, 54868460700, 
69238155406, 51862002801, 51862002806, 52544094928, 
54569579800, 54868621000, 54569645500, 68462038829, 
68462038884, 54868050700, 00254203273, 00254203280, 
00254203291, 00603763417, 00603763449, 50090138000, 
54569644200, 00555902058, 00555902079, 52544096691, 
54569655600, 54868231600, 16714036601, 16714036603, 
51862054501, 51862054506, 52544096728, 00781557515, 
70700011884, 70700011885, 54569427301, 00378727753, 
17478026106, 17478026128, 33261012001, 50090260300, 
54569669600, 68180083811, 68180083813, 68180083871, 
68180083873, 68462056529, 71205017028, 71205019128, 
00062191000, 50458019106, 50458019115, 50458019128, 
54868409300, 00062125100, 50458025106, 50458025115, 
50458025128, 54569549300, 54569549302, 54868473000, 
50090323900, 54569675800, 69238160706, 00781406015, 
70700012184, 70700012185, 16714036301, 16714036304, 
00781406215, 70700012084, 70700012085, 50090242900, 
54569666700, 63187075428, 68180083711, 68180083713, 
68180083771, 68180083773, 65862077828, 65862077885, 
00093214028, 00093214062, 54569664100, 65862077728, 





54569628100, 54569628101, 00555901858, 50102023311, 
50102023313, 50102023111, 50102023113, 52544024828, 
54569579600, 54868582600, 52544008728, 52544008741, 
00781405815, 70700011984, 70700011985, 17478026006, 
17478026028, 50090225900, 50090345400, 68180084011, 
68180084013, 69238155106, 65862077628, 65862077685, 
16714036001, 16714036004, 52544024728, 54569581600, 
00062190700, 50458019706, 50458019715, 50458019728, 
54868260600, 00254202980, 00254202991, 00603764217, 
54569628000, 54569628001, 00555901658, 53217009128, 
54868482800, 63187091128, 50102023511, 50102023513, 
55289088704, 63629266601, 52959046004, 00555904958, 
00555904979, 50090218300, 54569662300, 54868485100, 
16714036501, 16714036504, 54569067900, 54868042800, 
55289024608, 51862056401, 51862056406, 52544084728, 
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